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ABSTRACT
Many antiproliferative G-quadruplexes (G4s) arise
from the folding of GT-rich strands. Among these,
the Thrombin Binding Aptamer (TBA), as a rare exam-
ple, adopts a monomolecular well-defined G4 struc-
ture. Nevertheless, the potential anticancer proper-
ties of TBA are severely hampered by its anticoag-
ulant action and, consequently, no related studies
have appeared so far in the literature. We wish to
report here that suitable chemical modifications in
the TBA sequence can preserve its antiproliferative
over anticoagulant activity. Particularly, we replaced
one residue of the TT or TGT loops with a diben-
zyl linker to develop seven new quadruplex-forming
TBA based sequences (TBA-bs), which were studied
for their structural (CD, CD melting, 1D NMR) and bi-
ological (fibrinogen, PT and MTT assays) properties.
The three-dimensional structures of the TBA-bs mod-
ified at T13 (TBA-bs13) or T12 (TBA-bs12), the former
endowed with selective antiproliferative activity, and
the latter acting as potently as TBA in both coagu-
lation and MTT assays, were further studied by 2D
NMR restrained molecular mechanics. The compar-
ative structural analyses indicated that neither the
stability, nor the topology of the G4s, but the differ-
ent localization of the two benzene rings of the linker
was responsible for the loss of the antithrombin ac-
tivity for TBA-bs13.
INTRODUCTION
Aptamers are short, structured, single-stranded RNA
or DNA ligands characterized by high affinity for their
target (1). Thanks to their elevated potential in diagnostic
and in therapeutic applications (2,3), as well as in bio-
engineered constructs (4–6), aptamers are, currently, one
of the most investigated class of protein ligands. Many
reported aptamers are G-Rich Oligonucleotides (GROs)
that bind their targets adopting G-quadruplex (G4)
structures (7–9). Very importantly, cell-based screening
showed that some GROs selectively act as antiproliferative
agents (10–13), including AS1411 (12,14–18) (also named
AGRO 100, T3G2TG2TG2TG2TG2T2GTG2TG2TG2);
T40214 (19,20) (G3CG3CG3CG3C); TG-ONs (21) [Telom-
eric G-tail Oligonucleotides, (T2AG3)n]; T-oligo (22,23)
(5′-pG2T2AGTAG2T3); enriched deoxyguanosine T-oligo
(24) (G2T2)4; Pur27 (25) (TG4AG3TG4AG3TG4A2G2); T-
22AG (26) (G3A2GAG3A2GAG5AG2). From the analysis
of the literature data, it emerges that the antiproliferative
activity is usually associated with GROs incorporating
GT-rich or GA-rich sequences (11).
Experimental evidence correlate the antiproliferative ac-
tion of GROs with the ability to engage a common path-
way of cancer cells, triggering the events that lead to cell
death (11,21). It is also inferred that GROs can target a
specific protein of cancer cells. For example, AS1411 binds
with high affinity to nucleolin, a nucleolar protein over ex-
pressed in cancer cells (16,18,27), whereas T40214 binds to
Stat-3/DNA complex (19,20).
Recently published data further stimulate the debate
about the exact mechanism of action of antiproliferative
GROs. Indeed, Zhang et al. (28) found that the antiprolifer-
ative activity of GROs, including AS1411 that is currently
being tested in phase II clinical trials (29), might be con-
tributed by the cytotoxicity of their guanosine-based degra-
dation products. However, some new emerging mechanistic
studies strongly suggest that GROs act, at least in part, as
antiproliferative agents through their GRO sequences and,
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consequently, through their ability to fold into G4 struc-
tures (30,31).
While it is reasonable to suppose that GROs can target
cancer cells through different pathways, poor information,
if any, about the structure-activity relationships (SARs) be-
tweenG-quadruplex typologies and protein interactions are
available. Indeed, almost all anticancer GROs are charac-
terized by a high grade of structural polymorphism (32–
34). They form in solution several G4 structures differing
for the molecularity and/or loop arrangement (35). There-
fore, the possibility to fully understand the SAR of each
oligodeoxynucleotide (ODN) is definitely subject to the
availability of biologically active sequences forming single
and well-defined G-quadruplex structures.
Interestingly, a cell-based screening of several
GROs demonstrated that the GT-rich 15-mer ODN
G2T2G2TGTG2T2G2 (36–44) (TBA, thrombin binding
aptamer, an ODN binding and inhibiting thrombin), pos-
sesses a significant antiproliferative activity (45). Moreover,
an electrophoretic mobility shift assay showed that TBA,
like AS1411, is able to bind to a nucleolar protein, thought
to be nucleolin (45). A powerful correlation between
the stability of the TBA tertiary structure and the two
related functional effects has been shown as well. Both
the anticoagulant (46) and the antiproliferative efficiencies
(45) of TBA are enhanced in the presence of K+ ions,
which are known to promote and stabilize the structuration
of TBA into a monomolecular chair-type antiparallel
G-quadruplex.
Additionally, recently reported data suggested that an-
tiparallel G-quadruplex forming ONs, including TBA, ac-
cumulate into mitochondria of CL1–0 living cells (47). Into
this cellular district, G4 structures could occur to regu-
late some essential events (48–51). In particular, it has been
shown that NOA1, a large GTP binding protein (52), binds
some parallel and antiparallel G-quadruplex forming ONs
(51).
Unfortunately, the potential of the TBA G4 as a molec-
ular tool in cancer research is strongly limited by its high
affinity to thrombin and to most of the thrombin precur-
sors (53). Still, since no connection between anticoagulant
and antiproliferative activities is apparent, different TBA
regions and/or different binding mode with its biological
targets are most likely involved, thus giving the opportu-
nity to perform SAR studies of the two biological effects
separately. Therefore, in the quest for new TBA analogues
endowed with increased antiproliferative activity, it is not
unreasonable to start investigating chemical modifications
of TBA sequence that, safeguarding the G4 tertiary struc-
ture, selectively quench its anti-thrombin activity. In the
light of this reasoning and of the literature data concern-
ing the TBA/thrombin interaction (38–43) and the related
SARs, (54–65) we have synthesized a pool of seven new
15-mer TBA analogues (TBA-bs), each of them containing
a dibenzyl linker replacing one nucleoside in the loop re-
gions. The new TBA analogues were investigated for their
structural and biological properties. CD and NMR mea-
surements indicated that most of the new analogues were
able to fold into monomolecular ‘chair-like’ G4s very simi-
lar to that adopted by the TBA. Biological results obtained
by performing the fibrinogen, prothrombin time (PT) and
Methylthiazol Tetrazolium (MTT) tests, indicated that two
out of the seven derivatives (TBA-bs4 and TBA-bs13) lost
the antithrombin and anticoagulant activities but preserved
(TBA-bs4) or enhanced (TBA-bs13) the antiproliferative
activity with respect to the TBA. The NMR based molec-
ular model of the G4 formed by TBA-bs13 suggested that
the dibenzyl linker could obstruct the binding of TBA-bs13
to thrombin, by steric hindrance in the inner region delim-
ited by the TT loops, thus determining the exclusive switch
of the biological activity toward the antiproliferative one.
Taken together, the presented results provide the first ev-
idence that the biological activities of the G4 tertiary struc-
ture of the TBA can be ‘controlled’ by a single site-specific
chemical modification.
MATERIALS AND METHODS
Chemicals and anhydrous solvents were purchased from
Fluka-Sigma-Aldrich. TLCs were run on Merck silica gel
60 F254 plates. Silica gel chromatography was performed
using Merck silica gel 60 (0.063–0.200 mm). The API 2000
(Applied Biosystems) mass spectrometer was used to per-
form the analyses of the intermediates and the monomer.
NMR data were collected on Varian Mercury Plus400 and
UNITYINOVA 500 MHz spectrometers equipped with a
broadband inverse probe with z-field gradient, and on a
Varian UNITYINOVA 700MHz spectrometer equipped with
a triple resonance cryoprobe. The data were processed us-
ing the Varian VNMR and the iNMR (http://www.inmr.
net) software packages. Reagents and phosphoramidites for
DNA syntheses were purchased from Glenn Research. ON
syntheses were performed on a PerSeptive Biosystem Ex-
pedite DNA synthesizer. HPLC purifications and analyses
were carried out using a JASCOPU-2089 PlusHPLCpump
equippedwith a JASCOBS-997–01UVdetector. CD exper-
iments were performed on a JASCO 715 spectropolarime-
ter equipped with a PTC-348 temperature controller. The
fibrinogen assay was performed using a JASCO 530 UV
spectrophotometer equipped with the PTC-348 tempera-
ture controller.
Synthesis of monomer phosphoramidite building block 3
Compound 2. 2,2-dibenzylpropane-1,3-diol (1.0 g, 4.1
mmol), 4,4′-dimethoxytrityl chloride (696.0 mg, 2.0 mmol)
and 4-dimethylaminopyridine (25 mg, 0.21 mmol) were dis-
solved in dry pyridine (20 ml) and dry CH3CN (10 ml).
The resulting solution was stirred at room temperature (r.t.)
under argon for 1.5 h. Dry methanol (200 l) was then
added to quench the reaction. After 30 min under stir-
ring, the solution was concentrated under reduced pressure
and the residue purified by column chromatography on sil-
ica gel (eluted with 90:10:0.1 DCM/MeOH/Et3N) to give
monodimethoxytritylated 2 as a clear white solid (40% yield
from 1; Rf 0.7 in DCM/MeOH 90:10 v/v).
1H NMR (400 MHz, CDCl3)  ppm 7.26–7.00 (19H);
6.90 (4H); 3.78 (s, 6H); 3.72 (s, 2H); 3.45 (s, 2H); 2.89 (s,
2H); 2.47 (s, 2H).
13C NMR (100 MHz, CDCl3)  ppm 156.1; 145.5; 139.9;
137.2; 130.0; 129.8; 129.2; 128.2; 127.4; 127.0; 126.6; 126.4;
124.2; 113.9; 89.1; 69.9; 60.7; 55.8; 40.5; 39.4.
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ESI mass (positive mode) calculated 558.28; found 559.3
[M + H]+, 581.3 [M + Na]+.
Compound 3. 2 (425 mg, 0.76 mmol) was dried in vacuo
overnight before being dissolved in anhydrous DCM (8 ml)
and diisopropylethylamine (530 l, 3.0 mmol) under argon.
268 l of -cyanoethyl diisopropylchlorophosphoramidite
was then added (1.2 mmol). After 40 min, the reaction was
diluted with ethyl acetate (15 ml), and finally washed with
10% sodium carbonate solution (15 ml) and brine (15 ml).
The organic layer was dried on magnesium sulphate and
concentrated in vacuo. The residue was purified by silica gel
chromatography eluted with DCM, ethyl acetate and tri-
ethylamine (80:10:10). The fractions containing the product
were collected and concentrated under vacuum, yielding 3
as white foam (85% yield; Rf 0.65 in CHCl3/MeOH/Et3N
97:3:0.05 v/v/v).
1H NMR (400 MHz, CDCl3)  7.90–6.85 (23H); 3.90
(2H); 3.76 (6H); 3.65 (2H); 3.60 (2H); 3.45 (2H); 3.39−3.02
(2H); 2.60−2.45 (4H); 1.09 (6H); 1.04 (6H).
13C NMR (175 MHz, DMSO-d6)  158.6; 151.6; 147.3;
139.4; 135.1; 130.3; 129.1; 127.8; 127.7; 127.1; 126.4; 126.1;
124.2; 113.1, 90.5; 71.2; 64.4; 60.4; 55.2; 47.3; 33.6; 29.7;
27.6; 20.9; 19.3; 17.3.
ESI mass (positive mode) calculated 758.3; found 759.9
[M + H]+, 781.9 [M + Na]+.
Synthesis of oligomers
TBA and TBA-bs were synthesized using standard solid
phase DNA chemistry on a controlled pore glass (CPG)
support following the -cyanoethyl phosphoramidite
method (66,67). The coupling time for the modified
monomer was prolonged from 2 min to 10 min. The
oligomers were detached from the solid support and de-
protected by treatment with an aqueous ammonia solution
(33%) at 55◦C overnight. The combined filtrates and
washings were concentrated in vacuo, dissolved in H2O,
and purified by HPLC using an anionic exchange column
eluted with a linear gradient (from 0% to 100% B in 30
min) of phosphate buffer at pH 7.0 (A: 20 mM NaH2PO4
aqueous solution containing 20% CH3CN; B: 1.0 M
NaCl, 20 mM NaH2PO4 aqueous solution containing
20% CH3CN, elution time 18.9 min). The oligomers were
successively desalted by molecular exclusion chromatog-
raphy on Biogel P-2 Fine. The purity (95%) was checked
on HPLC using an analytical reverse phase column (Phe-
nomenex, Clarity Oligo-RP, 3 m, 2 × 10 mm) eluted with
a gradient of CH3CN in triethylamine acetate (pH = 7.4,
CH3CN from 0% to 100% in 40 min). The concentrations
of the samples used in CD and UV experiments were
determined by measuring the absorbance at 260 nm at
80◦C and using the open access program available at
http://basic.northwestern.edu/biotools/OligoCalc.html
(68).
CD experiments
To perform the CD experiments on modified TBA se-
quences, each ON was dissolved in K+ buffer (90 mMKCl,
10 mM KH2PO4, pH 7.4) or PBS (Phosphate Buffered
Saline) at the final ON concentration of 2.0 × 10−5 M and
submitted to the annealing procedure (heating at 90◦C for
5 min and slowly cooling at r.t.). Before each experiment
the samples were equilibrated at 10◦C for 30 min. CD spec-
tra were recorded from 200 nm to 400 nm at 100 nm min−1
scanning rate, 16 s response, 2.0 nm bandwidth, cell length
0.1 cm, vol 400 l. Each CD profile was obtained by taking
the average of three scans. CDmelting curves were obtained
by monitoring the variation of absorbance at 295 nm from
10◦C to 90◦C, cell length 1 cm, vol 1400 l, temperature
scan speeds of 0.1 and 0.5◦C min−1.
Furthermore, the CD melting experiments in K+ buffer
were also performed at ON concentrations of 1.0 × 10−4
and 8.3 × 10−6 M. These samples were obtained by di-
luting a 1.0 × 10−3 M sample, properly annealed in K+
buffer. The samples at 1.0 × 10−4 M were subjected to the
melting-annealing experiments (cell length 0.1 cm, vol 400
l), whereas those at 8.3× 10−6 M to the annealing-melting
experiments (cell length 0.5 cm, vol 1200 l). The tempera-
ture scan speed was fixed at 0.2◦C min−1.
Fibrinogen clotting assay
The fibrinogen clotting times were measured spectropho-
tometrically following the procedure previously described
(69). ONs were incubated for 1 min at 37◦C in 1.0 ml of PBS
containing 2.0mg/ml of fibrinogen (fibrinogen fromhuman
plasma, F 3879, Sigma-Aldrich) in a PMMA cuvette (vol
1.5 ml, cell length 1 cm, Brand). 100 l of human thrombin
(10 NIH per ml; Sigma-Aldrich, T8885, human thrombin
suitable for the thrombin time test) was then added to the
solution containing the fibrinogen and the ON. For each
ON, three sets of experiments at concentration of 20, 50,
100 nM were performed. The time required for fibrin poly-
merization was determined from the UV scattering curve,
registered, as a function of time (wavelength fixed at 380
nm), in triplicate for each ON concentration. The clotting
time value reported as mean ± SE was derived as the maxi-
mum of the second derivative of each scattering curve. The
basal clotting time (25.6± 1.5 s) was referred to the clotting
time value determined in absence of any ONs.
NMR experiments
NMR samples were prepared in PBS/D2O (90:10, v/v)
at a single strand concentration of about 5 mM. One-
dimensional NMR spectra were acquired as 16384 data
points with a recycle delay of 1.0 s at 25◦C. Data sets were
zero filled to 32768 points prior to Fourier transforma-
tion and apodized with a shifted sine bell squared window
function. Two-dimensional NMR spectra of TBA-bs12 and
TBA-bs13 were acquired at 10◦C using a recycle delay of
1.2 s. NOESY spectra were acquired with mixing times of
100, 200 and 300 ms. TOCSY spectra were recorded with
the standard MLEV-17 spin-lock sequence and a mixing
time of 80 ms. Water suppression was achieved by includ-
ing a double pulsed-field gradient spin-echo (DPFGSE)
module (70,71) in the pulse sequence prior to acquisition.
In all 2D experiments, the time domain data consisted of
2048 complex points in t2 and 400 fids in t1 dimension.
The sequence-specific resonance assignment of all proton
signals of TBA-bs12 and TBA-bs13 was obtained using
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Figure 1. Synthesis of phosphoramidite building block. i) 2,2-
dibenzylpropane-1,3-diol 1 (1.0 g, 3.9 mmol), 4,4′-dimethoxytrityl
chloride (0.69 g, 3.9 mmol), 4-dimethylaminopyridine (2.5 × 10−2 g,
0.21 mmol) dry Py (10.0 mL), dry CH3CN (10.0 mL), 2.5 h, yields
40%; ii) 2 (0.425 g, 0.76 mmol), -cyanoethyl-N,N’-diisopropyl-chloro-
phosphoramidite (0.270 mL, 1.2 mmol), DIPEA (0.530 mL, 3.0 mmol),
dry DCM (8 mL), 1.0 h, 85%.
NOESY and TOCSY spectra following the standard pro-
cedure (72,73).
Molecular modelling
The initial structure of TBA-bs12 and TBA-bs13 was built
using as the starting point the coordinates of the NMR so-
lution structure of TBA quadruplex (PDB id. 148D) (44).
The nucleoside T12 or T13, respectively, was replaced with
the linker 1 (Figure 1) by using the builder module of the
Insight II (2005) software package (Accelrys). The obtained
molecules were parameterized according the AMBER force
field and the atom of the linker 1 were selectively mini-
mized using the steepest descent and conjugate gradient
minimization methods until convergence to a RMS gradi-
ent of 0.001 Kcal mol−1 was reached. The structures were
then neutralized by adding 14 sodium counterions and sol-
vated in a square TIP3P water box (38 × 38 × 38 A˚). Water
molecules were minimized (RMS ≤ 0.1 Kcal mol−1) and
the systems were subjected to NMR-restrained energy min-
imization (steepest descent and conjugate gradient methods
until convergence to a RMS gradient of 0.001 Kcal mol−1)
as described below. The systems were first minimized us-
ing the following restraints: 109 or 75 quadratic interpro-
ton distances (fixed-length; 30 Kcal mol−1 force constant)
for TBA-bs12 or TBA-bs13, respectively; 32 flat-bottomed
hydrogen bond constraints (16 hydrogen/acceptor 1.7–2.0
A˚ and 16 donor/acceptor 2.7–3.0 A˚; 100 Kcal mol−1); 5
glycosidic torsion angles constrained to a range of –160◦/–
70◦ (flat bottomed; 200 Kcal mol−1) as required for anti
Gs; 4 glycosidic torsion angles constrained to a range of
10◦/100◦ (flat bottomed; 200 Kcal mol−1) as required for
syn Gs. Next, the distance restraints were removed and the
systems were subjected to a second minimization. Finally,
all restraints were removed and a final energy minimization
was performed. All calculations were repeated 10 times on
each system until convergence at the RMS gradient ≤0.001
Kcal mol−1 was reached. For each system the average min-
imized structure was then obtained by using the analysis
module of the Insight II 2005 software package. The aver-
age RMSD value was 0.988 A˚ for TBA-bs12 and 0.983 A˚
for TBA-bs13.
Prothrombin (PT) Time
PT time was measured by using a Koagulab MJ Co-
agulation System with a specific kit RecombiPlas Tin
HemosIL (Instrumentation Laboratories, Lexington, MA,
USA). The procedure was performed according to theman-
ufacturer’s instructions. In our experimental protocol a time
course (up to 15 min) of each ON or vehicle with 100 l of
plasma at 37◦C was performed. In details, 2.0 l of the cor-
responding ON solution (1.0×10−3 M in PBS) or vehicle
(PBS) was added in the apposite microtube, to achieve the
final concentration of 20 M. Similarly, to reach the final
concentration of 2 M, 2.0 l of 1.0 × 10−4 M ON solu-
tion was added to 100 l of plasma at 37◦C. Next, 200 l
of the kit solution containing Recombiplastin was added
with consequent activation of the extrinsic pathway. The
PT measurement was produced in triplicate, and the aver-
age and its standard error values were calculated. The basal
clotting timewas determined bymeasuring the clotting time
in the absence of anyON (13.4± 0.2 s). The incubationwith
PBS did not modify the PT measurement.
MTT test
He-La cervical carcinoma cells were seeded in a 96-well
plate at a density of 250 cells/well in Dulbecco’s modified
Eagle’s medium supplementedwith 10% fetal bovine serum.
Briefly, 24 h after being cultured, cells were treated with the
different ONs for 7 days and afterward 20 l of MTT so-
lution (5 mg/ml, Sigma-Aldrich) was added into each well
and incubated for 4 h. The growth medium was then re-
moved and replaced with 4 mM HCl, 0.1% Nondet P-40
(NP40) in isopropanol (150 l/well) in order to dissolve the
blue-purple crystals of formazan. The absorbance was then
measured using aMicroplate Reader at 595 nm. Cell viabil-
ity of triplicate cultures was assessed and graphed together
with the corresponding standard deviation.
RESULTS
Synthesis of ONs
The synthesis of derivative 3 (Figure 1) started from the
commercially available 2,2-dibenzylpropane-1,3-diol (1),
that was subjected to the standard protection of one al-
coholic function with 4,4′-dimethoxytrityl group. The pro-
tected product 2 was then reacted with -cyanoethyl-N,N’-
diisopropyl-chloro-phosphoramidite to obtain 3. This
monomer was used to automatically synthesize the modi-
fied ONs reported in Table 1 using the standard phospho-
ramidite protocol (66,67). The length of the coupling cycle
using the new monomer 3 was extended from 2 min to 10
min. The yields of coupling were similar to those obtained
using the standard phosphoramidite building blocks.
CD and CD melting
The folding of TBA into the monomolecular antiparallel
chair-like G-quadruplex structure causes a well known CD
profile characterized by three positive bands at 212, 247 and
295 nm and a negative band around 270 nm (74–76). In-
deed, CD spectroscopy is commonly used to quickly valu-
ate the effects of sequence modifications on the general fea-
ture of TBA G-quadruplex (43,54–64,74–76). To this pur-
pose we performed CD analyses both in PBS (Figure 2) and
K+ buffer (Supplementary Figure S1). From collected data
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Table 1. TBA-based sequences (TBA-bs) containing 2,2-dibenzylpropane-1,3-diol (X) at the indicated position
ON Sequence
TBA G1G2T3T4G5G6T7G8T9G10G11T12T13G14G15
TBA-bs3 G1G2X3T4G5G6T7G8T9G10G11T12T13G14G15
TBA-bs4 G1G2T3X4G5G6T7G8T9G10G11T12T13G14G15
TBA-bs7 G1G2T3T4G5G6X7G8T9G10G11T12T13G14G15
TBA-bs8 G1G2T3T4G5G6T7X8T9G10G11T12T13G14G15
TBA-bs9 G1G2T3T4G5G6T7G8X9G10G11T12T13G14G15
TBA-bs12 G1G2T3T4G5G6T7G8T9G10G11X12T13G14G15
TBA-bs13 G1G2T3T4G5G6T7G8T9G10G11T12X13G14G15
X = 2,2-dibenzylpropane-1,3-diol.
Figure 2. CDprofiles of TBA and TBA-based sequences. Spectra were col-
lected at 10◦C, using [ON] of 2.0×10−5 M in PBS.
it appears that almost all new ONs in both used buffers fold
into structures that display a CD profile very close to that of
TBA.However, in some cases slight differences in the profile
or in the intensity of bands were revealed. To analyze these
effects as a function of the position occupied by dibenzyl
linker along the sequence, the collected data were divided
into two sets.
According to NMR and X-ray data, that designate the
residues at position 4, 8, 9 and 13 as essential for the topol-
ogy and the stability of the G4 structure (37–41,43), we
grouped the CD profiles of the corresponding TBA-bs vari-
ants in Figure 2, panel A. Notably, the CD spectra of TBA-
bs8 and TBA-bs9 showed a significant decreasing in the in-
tensity of theCDband at 292 nm, compared to that of TBA.
Furthermore, the spectra of the variants (Figure 2A) con-
taining the linker 1 at position 4 or 9 or 13 were strongly
similar to each other and slightly differed from that of TBA
by a more negative CD signal in the range 230–270 nm.
The CD spectra of TBA-bs modified at position 3 or 7 or
12 are shown in Figure 2, panel B. All the variants in this
group preserved almost unchanged the CD profile of TBA.
The only difference we observed was a slight decrease in the
intensity of the positive CD bands for TBA-bs3 and TBA-
bs7.
To evaluate the thermal stability of the folded G-
quadruplexes we performed CD melting experiments. The
melting curves (Supplementary Figure S2) were registered
monitoring the change of the intensity of the band at 295
nm increasing the temperature from 10◦C to 90◦C. The de-
rived apparentmelting temperatures (Table 2) indicated that
the thermal stability of TBA-bs4 and TBA-bs13 G4s was
slightly higher than that measured for TBA (Tm ∼3–4◦C
in both PBS andK+ buffer) whereas that of TBA-bs3, TBA-
bs7 and TBA-bs12 was almost unchanged. In contrast,
TBA-bs8 and, especially, TBA-bs9 folded into G4s consid-
erably less stable than that of TBA in both K+ buffer (Tm
-4.3 and -15.5◦C, respectively) and PBS. Furthermore, in the
case of TBA-bs9, as a result of the poor structure stability
in PBS, it was not possible to calculate the melting tempera-
ture from the corresponding melting curve (Supplementary
Figure S2).
Finally, to probe the molecularity of the G-quadruplexes,
all the CD melting experiments in K+ buffer were also per-
formed on samples at the two additional strand concentra-
tions of 1.0 × 10−4 and 8.3 × 10−6 M (12-fold relative di-
lution). For all TBAs, we did not observe significant dif-
ferences between the two sets of melting profiles (Supple-
mentary Figure S3a–S3g), thus suggesting that themodified
ONs preserve the ability of TBA to fold into monomolecu-
lar G4s (77).
NMR structural characterization
The ability of all the here reported TBA-bs to fold into
a TBA-like antiparallel quadruplex was also assessed by
NMR spectrometry. The 1H NMR spectrum of TBA an-
nealed in Na+ or K+ containing buffer is characterized by
the presence of eight well resolved signals in the 11.5–12.5
ppm region, attributable to the exchange protected imino
protons involved in the formation of two G tetrads, and by
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Table 2. Thermal stability and biological properties of TBA and TBA-based sequences. The apparent melting temperatures (◦C) were measured as mini-
mum in the first derivative of CD melting profiles
Name aTm (◦C) bTm cTm (◦C) bTm dw/o ± eSD 10 M fPT ± gSE 20 M
TBA 50.7 0 35.1 0 0.669 ± 0.054 49.8 ± 1.28
TBA-bs3 50.0 -0.7 35.4 +0.3 0.996 ± 0.045 43.6 ± 2.15
TBA-bs4 51.9 +1.2 37.2 +2.1 0.700 ± 0.093 14.1 ± 0.25
TBA-bs7 50.0 -0.7 34.5 -0.6 0.400 ± 0.103 56.3 ± 0.97
TBA-bs8 46.4 -4.3 34.4 -0.7 0.811 ± 0.047 25.8 ± 0.30
TBA-bs9 35.3 -15.4 hn.d hn.d. 1.087 ± 0.1059 24.8 ± 0.80
TBA-bs12 51.1 +0.4 35.4 +0.3 0.739 ± 0.031 52.0 ± 1.73
TBA-bs13 53.3 +2.6 38.9 +3.8 0.498 ± 0.103 12.5 ± 0.55
aAnnealing buffer: 90 mM KCl, 10 mM potassium phosphate, pH 7.4.
bCalculated respect to TBA melting temperature.
cAnnealing buffer: PBS, pH 7,4.
dRatio between measured absorbance in MTT test in presence and in absence of ONs.
eStandard Deviation.
fMeasured Prothrombin Time in human plasma.
gStandard Error.
hnot determinable.
fifteen aromatic proton signals (6.8–8.5 ppm) attributable to
H8 and H6 protons of guanine and thymine bases, respec-
tively. Moreover, two peculiar upfield-shifted methyl sig-
nals of mutually H-bonded T4 and T13 are seen at around
1.0 ppm (37,40,41). Finally, the alternating syn-anti-syn-
anti glycosidic bond conformation within the two stacked
G-tetrads, typical of most antiparallel quadruplexes, is ob-
served. As for the TBA, the quadruplex diagnostic imino
signals were observed in the water suppressed 1H NMR
spectra of the here reported TBA-bs, with the noticeable
exception of TBA-bs8 (for some examples see Figure 3 and
Supplementary Figure S4a–S4e). Hence, the replacement of
a single T residue in one of the three loops for the dibenzyl
linker did not impede the quadruplex formation, whereas
the replacement of G8, the only guanosine in the sequence
not engaged in the two G-tetrads, did it. In particular, as
we already observed in our previous papers (54,60,64), the
replacement of T3 or T4 in the TBA sequence with acyclic
nucleoside analogues induces changes in the resultingNMR
profiles that are very similar to those induced when the re-
placement occurs at T12 or T13, respectively. It is interest-
ing to note that the similarity observed between members
of eachTBA-bs3/TBA-bs12 orTBA-bs4/TBA-bs13 couple
was also observed by CD and by fibrinogen or prothrom-
bin time assays (vide infra). According to the biological re-
sults, we undertook a detailed structural study of the G-
quadruplexes formed by TBA-bs12 and TBA-bs13 by using
the NMR-refined molecular mechanics approach.
Structural investigation of TBA-bs12. The 1H NMR spec-
trum of TBA-bs12 recorded at 25◦C (Supplementary Fig-
ure S4a) was characterized by the presence of eight partially
overlapped signals in the 11.9–12.3 ppm region attributable
to the exchange-protected imino protons involved in the for-
mation of Hoogsteen hydrogen bonds of two G-tetrads, in
close analogywith previous observations on the antiparallel
quadruplex formed by the unmodifiedTBA (41). Because of
the presence of the two benzene rings in the linker 1 at po-
sition 12, the aromatic portion of the 1H spectrum (6.8–8.5
ppm) was populated by more than the 14 signals belonging
to the protons of guanines and thymines of the G4 struc-
ture. In addition, other weaker signals belonging to one
or more minor conformations likely including the unfolded
form were observed in this region. With the aim of mini-
mizing the exchange between the G-quadruplex and the un-
folded form, we recorded the 1H NMR spectrum of TBA-
bs12 also at 10◦C (Figure 4, panel A). As expected, a general
simplification of the NMR spectrum was observed. In par-
ticular, at 10◦C most of the weaker signals disappeared and
an improved dispersion of the signals was obtained. The
combined analysis of 2DNOESY and TOCSY spectra (700
MHz, 10◦C) allowed us to get the nearly complete assign-
ment of exchangeable and non-exchangeable protons using
the standard procedure (Supplementary Table S1) (72,73).
The TOCSY data are not shown here, but they were used
to confirm the assignments based on the NOESY data.
The overall analysis of NOE connectivities and the eval-
uation of the  between TBA-bs12 and TBA (see Sup-
plementary Table S2) confirmed that TBA-bs12 adopts a
three-dimensional structure that is very similar to the TBA
chair-like antiparallel quadruplex. In particular, the anal-
ysis of the intranucleotide and internucleotides H8/H6 to
H1′ NOE connectivities (Figure 4, panel B) confirmed that
four out of the eight guanosines involved in the two G-
tetrads adopt the syn glycosidic bond conformation, as seen
for TBA. TheNOE connectivities between themethyl signal
of T9 and four imino protons confirmed that T9 is stacked
above the G1-G15-G10-G6 G-tetrad (syn Gs are under-
lined) (Figure 4, panel C). Finally, the very lowobserved
for the methyl signal of T4 ( 1.07 ppm;  0.04 ppm) dis-
closed that the substitution of T12 with the linker 1 did not
interfere with the tertiary structure adopted by TBA-bs12,
even in the close proximity of the substitution site, and sug-
gested that the two benzene rings could not occupy the cleft
delimited by the two TT loops (37,40,41,44). The latter ob-
servation is noteworthy, considering that most of the X-ray
diffraction data of TBA-thrombin complexes have shown
that the TBA recognizes the thrombin anion-binding ex-
osite I (ABE I; also known as the fibrinogen exosite) by us-
ing the T3-T4 and T12-T13 loops (37,39–43,54,60,61,64).
To get insights about the orientation of the benzene rings of
1with respect to the quadruplex scaffold, and to rationalize
the effects on the antiproliferative and antithrombin activi-
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Figure 3. Representative 1H NMR imino proton regions of TBA-bs incorporating the 2,2-dibenzylpropane-1,3-diol at the indicated position (25◦C; PBS
buffer, H2O/D2O 9:1).
ties shown by TBA-bs12, we performed a NMR-restrained
molecular mechanics study as described in Materials and
Methods. As we expected, among the 109 NMR interpro-
ton distances used in the calculations only a few involved
close contacts with the atoms of the linker 1, and the re-
sulting averaged structure confirmed in full (Figure 5) that
in the G4 structure formed by TBA-bs12, the two benzene
rings are positioned aside from the G4 core, thus allowing
its recognition by the thrombin ABE I.
Structural investigation of TBA-bs13. The NMR struc-
tural elucidation of the G4 formed by TBA-bs13 in PBS
buffer was performed as described above for TBA-bs12 and
inMaterials andMethods. TheNMR characterization con-
firmed the formation of a stable antiparallel chair-like G4
stabilized by two G-tetrads (8 well resolved imino proton
signals; Figure 6, panel A) connected by the T3-T4, T12-
X13 and T7-G8-T9 loops. Intra- and inter-nucleotide NOE
connectivities confirmed that the methyl group of T9 is
stacked above the G1-G15-G10-G6 tetrad (Figure 6, panel
C) and that the two G-tetrads are made up of alternating
syn and antiGs (Figure 6, panel B). All together, the analy-
sis of the 1H chemical shifts (Supplementary Table S3) and
 between the NMR signals of TBA-bs13 and TBA (Sup-
plementary Table S4) indicated that the incorporation of the
dibenzyl linker at position 13 of TBAdoes not inducemajor
distortions in the resultingG4 scaffold.However, differently
from TBA-bs12, we observed a significant up-field shifting
for the imino protons of G5, G6, G10, G11, G14 and G15,
and a down-field shifting for the methyl signals of T4 and
T12. These NMR evidence suggested that the two benzene
rings of the linker were not projected aside the G4 core
as found for TBA-bs12. Accordingly, among the 75 NOE
distance restraints included in the calculations, 8 involved
NOE contacts between the atoms of the linker and those of
nucleosides G11, T12 andG14. The resultingminimized av-
erage structure of TBA-bs13 obtained by the NMR-refined
molecular mechanics calculations is shown in Figure 7. Ac-
cording to the simulated structure, the two benzene rings of
X13 are located in the pocket delimited by the twoTT loops.
In particular, the ring coloured in red in Figure 7 is stacked
exactly above the 6-membered ring ofG11, whereas the blue
ring is turned away the G2-G5-G11-G14 tetrad pointing at
the T3-T4 loop. These findings are in agreement with the
observed  caused by the strong benzene rings current.
Fibrinogen assay
In order to assess the effect on the enzymatic activity of
thrombin and to correlate the biological effects with the
structural data, the modified ONs were tested in the fib-
rinogen clotting assay. The thrombin-induced clotting of
fibrinogen was measured spectrophotometrically, following
the increase in absorbance at 380 nm as a function of time
(69). The assay was performed using 2 mg per ml of fibrino-
gen, 1 NIH of thrombin and various concentrations of each
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Figure 4. NMR study of TBA-bs12 annealed in PBS/D2O 9:1 (10◦C, 700 MHz). (A) 1H NMR spectrum. The expansion of the imino proton region is
shown in the inset. (B, C) Expansions of the 2D NOESY (200 ms mixing time) spectrum. The sequential H1′-H8 or H1′-H6 connectivities and the self-
peaks involving H1′ protons have been drawn in B using dotted lines and labels, respectively. NOE correlations between T9 methyl protons and H8 protons
of the G10-G1-G6-G15 tetrad are shown in C.
Figure 5. 3D average structure of TBA-bs12 obtained by NMR-
restrained molecular mechanics. Nucleotides are shown as sticks, the 2,2-
dibenzylpropan-1,3-diol linker as sticks and filled rings and the phosphate
backbone as a green solid ribbon.
aptamer (20, 50 and 100 nM). The comparison of result-
ing data (Figure 8 and Supplementary Table S5) evidenced
marked differences among the modified TBA-bs in their
ability to inhibit the fibrinogen clotting formation. TBA-
bs12 showed an increased inhibitory effect relative to the
unmodified sequence, at all explored concentrations. TBA,
TBA-bs3 and TBA-bs7 prolonged the fibrinogen clotting
time at almost the same extent. TBA-bs9 and, especially,
TBA-bs8 showed a significant decreased inhibitory effect
relatively to TBA. Most significantly, at all explored con-
centrations, TBA-bs4 and TBA-bs13 resulted totally unable
to compete with fibrinogen for the binding to the enzyme.
PT assay
To validate the results obtained from the fibrinogen clot-
ting assay, we performed PT tests on human plasma (PT
assay) (36,54,60,61). As shown in Figure 9 and in the Ta-
ble 2 and Supplementary Table S6, the PT values pointed
to a trend of the anticoagulant activities that was almost in
agreement with the antithrombin activities measured in the
fibrinogen assay. Major difference resulted in the behaviour
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Figure 6. NMR study of TBA-bs13 annealed in PBS/D2O 9:1 (10◦C, 700 MHz). (A) 1H NMR spectrum. The expansion of the imino proton region is
shown in the inset. (B, C) Expansions of the 2D NOESY (200 ms mixing time) spectrum. The NOE connectivities between atoms of X13 and nucleotides
atoms are traced and labelled in panel B. The sequential H1′-H8 or H1′-H6 connectivities and the self-peaks involving H1′ protons have been drawn in B
using dotted lines and labels, respectively. NOE correlations between T9 methyl protons and H8 protons of the G10-G1-G6-G15 tetrad are shown in C.
of TBA-bs12, which showed in fibrinogen assay, but not
in PT test, a significant increasing in the antithrombin effi-
ciency with respect to TBA. Herein, among the tested ONs,
TBA-bs7 proceeded as the best anticoagulant one. The PT
values measured in presence of TBA-bs4 or TBA-bs13 con-
firmed that these modified sequences were wholly unable to
inhibit thrombin.
MTT test
On the basis of literature data (45), all modified sequences
and TBAwere examined for their antiproliferative activities
against He-La cervical carcinoma cell line at three differ-
ent concentrations, 1 (Figure 10, panel A), 5 (Supplemen-
tary Figure S5) and 10 M (Figure 10, panel B and Ta-
ble 1). As a result, all but TBA-bs9 were judged to be ac-
tive against this tumor cell line. Specifically, TBA-bs7 and
TBA-bs13 had the greatest effect on the cell growth, at
all tested concentrations. Notably, TBA-bs4 and TBA-bs13
preserved the antiproliferative activity of TBA against He-
La cells, but, according to fibrinogen and PT data, lacked
in thrombin affinity. To better explore the antiproliferative
effect of TBA-bs13, dose-response experiments at concen-
trations between 1.0 × 10−3 and 50 M were performed.
The obtained clear dose-response curves indicated a 5-fold
increased cell growth inhibition for TBA-bs13 with respect
to TBA (Figure 11 and Supplementary Tables S7 and S8).
DISCUSSION
The findings that specific modifications of TT loops of TBA
negatively interfere with its thrombin affinity without af-
fecting the G-quadruplex stability (64), and that the an-
tiproliferative activity is a general property of GT-rich ON
strands (11) make ready the perspectives of modified TBAs
as selective antiproliferative ONs provided with the notable
advantage to fold into well defined G-quadruplex struc-
tures.
Aimed by this idea, we selected, among the commercially
available acyclic diols, the unusual dibenzyl-linker 1 (Figure
1) as the modifying agent for the obtainment of a series of
new TBA-based sequences (see Table 1) in which 1 (indi-
cated as X in Table 1) replaced one at the time the loop nu-
cleotides of TBA. Indeed, the linker 1 provided for: (i) two
hydroxyls, to make the required phosphoramidite building
block 3; (ii) an aromatic portion, to mimic the aptitude of
 at N
ational Library of H
ealth Sciences on N
ovem
ber 25, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2015, Vol. 43, No. 16 7711
Figure 7. 3D average structure of TBA-bs13 obtained by NMR-
restrained molecular mechanics. Nucleotides are shown as sticks, the 2,2-
dibenzylpropan-1,3-diol linker as sticks and red and blue filled rings and
the phosphate backbone as a green solid ribbon.
Figure 8. Fibrinogen clotting time (sec) in presence of each ON measured
at three different concentrations (20, 40 and 100 nM). The bars of control
and vehicle represent the fibrinogen clotting time values of the system in
absence of any ONs and diluted with the buffer alone, respectively.
Figure 9. PT values obtained following 15 min of ON incubation with hu-
man plasma at concentration of 20 M [ON]. Each measurement has been
performed in triplicate and it was shown as mean ± SEM. PT values are
expressed in seconds. The basal PT time is 13.4 ± 0.2 s. *** = P<0.001 vs.
vehicle; ◦,◦◦, ◦◦◦ = P<0.05, <0.01, <0.001 versus TBA.
some loop residues in the TBA G-quadruplex to stack on
the adjacent G-quartet (37–43); (iii) a moderate bulky por-
tion, to cause steric crash between the TBA G4 and throm-
bin (64). Finally, as the requirements were fulfilled into sym-
metrical molecules, it was also ensured that the insertion of
the linker did not give rise to diastereomeric nucleic acid se-
quences (54).
CD and 1H NMR studies performed on the new syn-
thesized TBA-bs suggested that the resulting G4 structures
strongly resembled that of the TBA (Figure 2, Supplemen-
tary Figures S1 and S4). Indeed, all CD profiles showed the
stronger positive band around 295 nm and a weak nega-
tive band around 270 nm, that are generally accepted as dis-
tinctive for antiparallel G4s structures (74–76). According
to the CD data, the G4 diagnostic imino signals were ob-
served in the 11.5–12.5 ppm region of the 1H NMR spectra
of the new derivatives (for some examples see Figure 3), as
for the TBA, with the exception of TBA-bs8. Furthermore,
in line with previous structural data which arranged the nu-
cleobases 3, 12 and 7 outside the G-quadruplex core (37–
43), the apparent CDmelting temperatures of the G4 TBA-
bs3, TBA-bs12 and TBA-bs7 were similar to that of TBA
(Supplementary Figure S2 and Table 2). Differently, sub-
stantial destabilization of the G4 structure occurred when
the linker 1 occupied the position 8 or 9 of the TGT loop
(Tm = -4.3 and -15.5◦C, respectively, compared to that of
TBA in K+ buffer; Supplementary Figure S2 and Table 2).
Given that T8 and G9 stack on the G1-G15-G10-G6 quar-
tet, thus stabilizing the TBA G-quadruplex core (37–43),
the obtained Tm values suggested that neither of the two
benzene rings of the linker 1 efficiently mimic the role of the
replaced nucleobase in theG4 structure formed byTBA-bs8
andTBA-bs9. Interestingly, stable antiparallel G4swere ob-
tained from the folding of TBA-bs4 and TBA-bs13 (Tm =
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Figure 10. Antiproliferative activity on He-La cervical carcinoma. Cells were treated with two different doses of ON, 1 (A) and 10 (B) M, annealed in K+
buffer (see experimental section). The bar NT (Not Treated) reports the cell viability in absence of ON. Cell viability was assayed seven days after addition
of ON using the MTT assay. A pool of three different sets of experiments (each repeated in triplicate) was performed, and each value expressed as mean ±
Standard Deviation.
Figure 11. Concentration-dependent response in MTT assay for TBA (A) and TBA-bs13 (B). Cell viability was assayed seven days after addition of ON
using theMTT assay. A pool of three different sets of experiments (each repeated in triplicate) was performed, and each value expressed asmean± Standard
Deviation.
51.9 and 53.3◦C, respectively, in K+ buffer; 37.2 and 38.9◦C
in PBS; Table 2), thus suggesting that the aromatic moieties
at position 4 or 13 could provide for the stacking interac-
tions with the nucleobase on the adjacent quartet (G2-G5-
G11-G14).
The results from PT and fibrinogen assays (Figures 8 and
9) allowed us to assess the involvement of the linker 1 in the
formation of TBA-thrombin complex, while those from the
MTT assay (Figure 10) the influence of 1 on the TBA cyto-
toxicity. By modifying the TGT loop, it resulted that TBA-
bs8 and TBA-bs9, that folded into the least stable G4 struc-
tures, still affected, although with reduced efficiency, the co-
agulation time measured in both the fibrinogen and PT as-
says (Figures 8 and 9; Supplementary Tables S5 and S6),
and showed the lowest antiproliferative effects in the MTT
test onHe-la carcinoma cell line (Figure 10 and Supplemen-
tary Figure S5). On the other hand, both the anticoagu-
lant activity and the cytotoxic effect of TBA-bs7 resulted
increased. These results could reflect a tighter correlation
between the structural stability ofG4s and the antiprolifera-
tive activity (11,21), than that observed with the antithrom-
bin efficiency (54,57,59–61,64). Indeed, among these three
ONs, the best-structured TBA variant (TBA-bs7) was also
the strongest growth-inhibitor agent and viceversa (TBA-
bs9). However, none of these ONs showed a selective action
with respect to the two functional effects. Consequently,
their G4 structures were not further investigated. The most
relevant outcomes emerged from TBA variants modified at
one residue of the TT loops. In fact, although the corre-
sponding G4s had Tm values very similar to each others
(T < 3.3◦C; Table 2), their biological properties were sig-
nificantly different. In the MTT assay (Figure 10 and Sup-
plementary Figure S5), TBA-bs4 and TBA-bs13, which re-
sulted totally unable to act as anticoagulant agents (Figures
 at N
ational Library of H
ealth Sciences on N
ovem
ber 25, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2015, Vol. 43, No. 16 7713
8 and 9; Table 2, Supplementary Figures S5 and S6), showed
significant cytotoxic effects on He-La cells, and TBA-bs13
was a better inhibitor of cell growth than TBA. Contrar-
ily, TBA-bs3 and TBA-bs12 afforded to a good correlation
between structure stability, antithrombin and antiprolifer-
ative activities (Figures 8–10 and Table 2). The biological
properties of the last two sequences were almost compara-
ble to that of TBA. Nevertheless, it was also observed that
the increased antithrombin activity of TBA-bs12 with re-
spect to TBA, measured in fibrinogen assay (Figure 8 and
Supplementary Table S5), was not observed in the PT test
(Figure 9, Table 2 and Supplementary Figure S6). Such in-
coherence between the fibrinogen and PT data was previ-
ously observed by us (60,61) and others (59,78) for other
TBA variants, and supports the hypothesis that the clot-
ting inhibitory activity of some modified TBAs could not
wholly depend on the ability of the aptamers to compete
with fibrinogen for thrombin ABE I. In fact, the presence
in the plasma medium of other thrombin effectors and/or
precursors (53), and the thrombin allostery (79), which reg-
ulates the complex thrombin action during homeostasis,
could also play an important role in determining the an-
ticoagulant effect of such type of TBA derivatives. How-
ever, the overall results evidenced that, despite the TBA G-
quadruplexwell sustained the replacement of oneTwith the
linker 1 at any position of the TT loops, the TBA-thrombin
complex did not tolerate such modification at T4 or T13.
Furthermore, the results were consistent with the TBA ter-
tiary structure, which leads residues T3 and T12, as well as
T4 and T13, to occupy equivalent positions with respect to
the G quartets (37–43). Nevertheless, TBA-bs12 and TBA-
bs13 are slightly more potent inhibitors of cell growth than
TBA-bs3 and TBA-bs4, respectively (Figure 10 and Sup-
plementary Figure S5). At the best of our knowledge, this
is the first evidence that loop structure is a further param-
eter capable to affect the antiproliferative efficiency of the
TBA G-quadruplex in addition to G4 stability.
To better understand the requirements to discriminate
between the antiproliferative and antithrombin effects, we
undertook an extensive 2D NMR study of the G4s formed
by TBA-bs12 and TBA-bs13 in PBS buffer. The inspec-
tion of the NMR-restrained molecular mechanics aver-
age G4 structure of TBA-bs12 (Figure 5) confirmed that
the two benzene rings of 1 are projected outside the G4
core. In contrast, in the corresponding average structure
obtained for TBA-bs13, the benzene ring coloured in red
in Figure 7 stacked exactly above the 6-membered ring
of G11, whereas the blue ring turned away the G2-G5-
G11-G14 tetrad pointing at the T3-T4 loop. These find-
ings agree in full with the anticoagulant activities showed
by TBA-bs12 and TBA-bs13. In fact, a lot of structure-
activity relationships and the analysis of severalX-rayTBA-
Thrombin complexes (38,39,42,43), showed that the TBA
G-quadruplex interacts with thrombin mainly through the
TT loops region. Particularly, essential polar interactions
between the nucleobases T4, T13 and G5 of the tertiary
structure and the side chains of Arg 77, Arg 75 and Tyr 76
located in the ABE I of the thrombin take place, whereas T3
and T12 are essentially involved into hydrophobic contacts
(43). Given that the dibenzyl linker was positioned outside
the TT loops, the modification at T12 did not provoke sub-
stantial alteration in the TT loops region of the resulting
G4, and almost all the above mentioned contacts between
TBA and thrombin could occur. As opposite to this, the G-
quadruplex bioactive conformation could be significantly
affected by the replacement of T13 with the dibenzyl linker
1, seeing that the two benzene rings occupied the region be-
tween the TT loops. Consequently, despite the overall topol-
ogy of the G4 formed by TBA-bs13 strongly resembled that
of TBA, the formation of a stable TBA-thrombin complex
was completely prevented.
Finally, the cytotoxic effect of TBA-bs13 on the He-La
cell line was studied in comparison with that of TBA by
means of MTT dose response experiments at concentra-
tions in the range of 0.001–50 M (Figure 11; Supplemen-
tary Tables S7 and S8). Inhibition of cell growth by TBA-
bs13 started at 0.1 M and reached the maximum effect at
10 M, whereas TBA produced the same effects at concen-
tration in the range of 1–50 M. Consequently, TBA-bs13
was significantly more potent than TBA in the inhibition of
He-La cell line growth.
Interestingly, it has been ascertained that some G4s bind
NOA1 (51), a large GTP binding protein involved in im-
portant mitochondrial functions such as the synthesis of
specific proteins, cellular respiration and apoptosis (52,80–
83). In particular, both parallel and antiparallel DNA G4s
are able to bind NOA1, but only the antiparallel ones also
cause an increasing of about 4–5 folds of the NOA1 GTP-
ase activity (51). The GTP dependent allosteric regula-
tion has also been established for other GTP binding pro-
teins involved in cancer development, survival and resis-
tance (84–86). In light of the ability of TBA (antiparallel
G-quadruplex) to accumulate intomitochondria (47), it will
be of interest to verify the existence of such connection be-
tween the antiproliferative activities of new TBAs onHe-La
cells and theNOA1 functionality intomitochondria and/or
in other cellular districts.
CONCLUSION
In conclusion, we showed that artful modifications in the
TBA could provide cytotoxic GROs which are able to fold
into the well known TBA G-quadruplex topology but de-
voided of the TBA anticoagulant action. In particular, the
replacement of the residue 4 or 13 with the dibenzyl linker 1
afforded two TBA variants, specifically TBA-bs4 and TBA-
bs13, which resulted unable to inhibit thrombin but showed
significant antiproliferative activity against the He-La cell
line. TBA-bs13 showed a 5-fold increased cell growth inhibi-
tion relative to the TBA as determined by theMTT dose re-
sponse assay. The data concerning the other modified TBAs
showed that none of them had a selective action relative to
either the biological properties of TBA. It is noteworthy that
TBA-bs9, which folded into the least stable G4, showed the
lowest antiproliferative activity at all the explored concen-
trations. A good correlation between the structure stability
and the antiproliferative action on He-La cells was also ob-
served for the other two TBA-bs modified at one residue
of the TGT loop, TBA-bs7 and TBA-bs8. Among the here
reported new analogues, TBA-bs7 showed to be the best
inhibitor of He-La cell line growth. Nevertheless, the pre-
sented data also demonstrated that more complex phenom-
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ena than the G-quadruplex stability control the difference
in the antiproliferative effects of the TBA-bs obtained by re-
placing one of the residues in the TT loops of the TBA with
the dibenzyl linker 1.
Although further deepened studies on these new TBA
variants are certainly necessary, we herein described a
potential route to obtain helpful G-quadruplex tools for
the understanding of the molecular factors that con-
tribute to the cytotoxicity of quadruplex-forming GROs
(27,28,30,31).
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